
Quo vadis, WZW criteria?
Switzerland's National Council has voted to tighten the WZW criteria. If you bring medicines, devices or diagnostics to the Swiss OKP, keep this on your radar.
On 29 September 2026, the National Council adopted Motion 26.4059, tabled by its own health committee (SGK-N). The Federal Council had already recommended acceptance. The motion now goes to the Council of States' committee (SGK-S) for preliminary review before the Council of States votes on it.
What the motion asks for:
1️⃣An amendment to KVG Art. 32 ff. to make the operationalisation of effectiveness, appropriateness and cost-effectiveness (WZW) more proportionate and, where needed, more precise. It should still leave room for implementation and avoid over-regulation.
2️⃣ A shift in the burden of proof. New, contested or not generally recognised services would only be reimbursed once efficacy is sufficiently shown with established scientific methods. Proof of effectiveness would become decisive, replacing the absence of proof of ineffectiveness.
3️⃣ WZW scrutiny extended to services already delivered and to billing between providers and insurers.
4️⃣ A new "guideline-gap" instrument. Where evidence is weak and clinical guidelines are missing, outdated, contradictory or inadequate, someone could formally demand new or updated guidelines. This explicitly covers more than physicians, naming home care (Spitex), laboratories and physiotherapy.
The rationale given is that the OKP still pays for too many services with a poor cost-benefit ratio. Parliament also wants BAG and EDI to base reimbursement limitations more closely on clinical guidelines. That could improve acceptance of limitations, case-by-case cost approvals and the administrative burden.
My read for industry:
🔹 Medtech and procedure-linked innovation: physician services today largely rely on the presumption that they meet WZW unless challenged. Moving toward proof of efficacy could raise the evidence bar for market entry.
🔹 Diagnostics: laboratories are named explicitly. Expect sharper questions on clinical utility.
🔹 Pharma: limitations in the Spezialitätenliste may increasingly mirror guidelines, so involvement in Swiss and European guideline development becomes a market access lever.
🔹 HEOR and market access teams: start planning Swiss evidence generation earlier, especially in therapy areas where guidelines are thin.
A caveat: this is a motion, not law. It still needs the Council of States, then a Federal Council draft bill and a full parliamentary debate. The details will matter, but the direction is clear.
